In this episode Dr. Brandon and Dr. Morgentaler talk about whether testosterone therapy is a lifelong commitment and explain why modern research shows testosterone does not drive prostate cancer and can be safely used in many men. 00:38 Debunking Testosterone Myths They start by clearing up the myth that starting testosterone therapy locks men into treatment for life and explain why people can safely stop and restart it. 03:13 Testosterone and Prostate Cancer Research They break down decades of research to show how early misconceptions shaped fear around testosterone and why modern data does not support those claims. 18:09 Testosterone's Role in Prostate Health They explain how testosterone functions as a normal requirement for prostate tissue and why adequate levels do not cause cancer growth. 21:04 Reevaluating Testosterone in Prostate Cancer Treatment They discuss why testosterone is being reconsidered even in certain prostate cancer cases and how newer studies challenge long-held medical assumptions. 25:17 Emerging Treatments and Future Directions The Dr's look ahead at evolving treatment approaches, ongoing research, and how updated evidence may change future care for men with low testosterone and prostate cancer. Resources: Morgentaler, A., & Traish, A. M. (2024). Testosterone does not drive prostate cancer: Introducing the framework of testosterone adequacy versus inadequacy. Journal of Urology. Morgentaler, A., & Traish, A. M. (2009). The saturation model of testosterone and prostate cancer. European Urology. Huggins, C., & Hodges, C. V. (1941). Early studies on testosterone and prostate cancer. Cancer Research. TRAVERSE Trial Investigators. (2023). Testosterone replacement therapy and prostate cancer outcomes. New England Journal of Medicine. Denmeade, S. R., et al. (2015). Bipolar androgen therapy (BAT) in advanced prostate cancer. Science Translational Medicine. With Dr. Abraham Morgentaler and Dr. Marianne Brandon Listen to the podcast on all of your favorite platforms: Apple: https://podcasts.apple.com/ec/podcast/the-sex-doctors/id1761813985?l=en-GB Spotify: https://open.spotify.com/show/0apSFzquJXKoOGnmI6ndgT?si=e5a1e482c7ca46c7 Find us on: Instagram: https://www.instagram.com/thesexdoctors?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw== Facebook: https://www.facebook.com/thesexdoctors YouTube: https://www.youtube.com/@thesexdoctorspod TikTok: https://www.tiktok.com/@thesexdoctor LinkedIn (Dr. Abraham): https://www.linkedin.com/in/abraham-morgentaler-md-81628b6 LinkedIn (Dr. Marianne): https://www.linkedin.com/in/mariannebrandon-59224513 X (Dr. Abraham): https://x.com/DrMorgentaler X (Dr. Marianne): https://x.com/drbrandon #TestosteroneTherapy #ProstateCancerMyths #TestosteroneAdequacy

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related